Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $52.40.

ESTA has been the subject of several analyst reports. BTIG Research initiated coverage on shares of Establishment Labs in a research note on Friday, May 16th. They set a “buy” rating and a $62.00 price target for the company. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research note on Saturday, June 14th. Stephens reaffirmed an “overweight” rating and set a $52.00 price target on shares of Establishment Labs in a research note on Thursday, March 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $48.00 price target on shares of Establishment Labs in a research note on Friday, June 13th.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds have recently bought and sold shares of the company. Mudita Advisors LLP raised its stake in Establishment Labs by 15.6% during the first quarter. Mudita Advisors LLP now owns 479,359 shares of the company’s stock worth $19,560,000 after buying an additional 64,859 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after purchasing an additional 9,557 shares in the last quarter. Boothbay Fund Management LLC increased its stake in Establishment Labs by 0.6% in the first quarter. Boothbay Fund Management LLC now owns 528,308 shares of the company’s stock valued at $21,558,000 after purchasing an additional 3,060 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Establishment Labs in the first quarter valued at $326,000. Finally, Redmile Group LLC increased its stake in Establishment Labs by 4.8% in the first quarter. Redmile Group LLC now owns 335,366 shares of the company’s stock valued at $13,685,000 after purchasing an additional 15,217 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $40.93 on Friday. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -13.20 and a beta of 0.74. The company has a debt-to-equity ratio of 5.72, a current ratio of 3.36 and a quick ratio of 2.05. The firm has a 50 day simple moving average of $35.37 and a 200 day simple moving average of $36.92. Establishment Labs has a one year low of $26.56 and a one year high of $52.41.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.58) EPS. Research analysts predict that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.